PT  - JOURNAL ARTICLE
AU  - KUNIKI KAWAGUCHI
AU  - KENJI NAKANO
AU  - TETSUYA URASAKI
AU  - NAOKI FUKUDA
AU  - SHINICHIRO TAIRA
AU  - MAKIKO ONO
AU  - JUNICHI TOMOMATSU
AU  - MASATOSHI NISHIZAWA
AU  - KEISUKE AE
AU  - SEIICHI MATSUMOTO
AU  - SHUNJI TAKAHASHI
TI  - Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma
AID  - 10.21873/invivo.11644
DP  - 2019 Sep 01
TA  - In Vivo
PG  - 1609--1614
VI  - 33
IP  - 5
4099  - http://iv.iiarjournals.org/content/33/5/1609.short
4100  - http://iv.iiarjournals.org/content/33/5/1609.full
SO  - In Vivo2019 Sep 01; 33
AB  - Background/Aim: Trabectedin is a synthetic antineoplastic agent approved for advanced soft tissue sarcoma (STS) in Japan. The aim of this study was to evaluate the efficacy and safety of the Japan-approved dose of trabectedin for advanced STS. Patients and Methods: We retrospectively reviewed 38 patients with advanced STS who received salvage chemotherapy with trabectedin. Results: The overall response and disease control rates were 16% (5 patients) and 67% (20 patients), respectively. The median progression-free and overall survival were 7.3 and 17.8 months, respectively. There were no significant differences between patients with liposarcoma or leiomyosarcoma and those without, or between patients with TRS and those without. The most common grade 3-4 AEs were elevated transaminases and neutropenia. Conclusion: Trabectedin 1.2 mg/m2, as the approved dose in Japan, showed similar efficacy to the dose of 1.5 mg/m2 used in Western countries. Trabectedin could be an option for advanced STS in Japan, regardless of histological subtype.